• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

New ERLEADA ® (apalutamide) Analysis Demonstrates Rapid, Deep Prostate-Specific Antigen (PSA) Response in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
SAN FRANCISCO, Feb. 14, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new real-world evidence data showing the initiation of ERLEADA® (apalutamide) results in high rates of rapid and deep prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC). In a separate post-hoc analysis of the registrational Phase 3 SPARTAN and TITAN studies, rapid and deep PSA responses with ERLEADA® were associated with improvement in patient-reported outcomes (PROs) related to quality of life, physical wellbeing, pain, and fatigue intensity. The...
Source: Johnson and Johnson - February 14, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news

Increased Risk of Lymphoid Malignancy in Patients with Herpes Zoster: A Longitudinal Follow-up Study Using a National Cohort Study
Conclusion: Our study demonstrates that herpes zoster infection increases the risk of subsequent lymphoid malignancies irrespective of age and gender in the Korean population.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Lee, Y. K., Kim, M., Kim, H. J., Lim, H., Choi, H. G. Tags: 902. Health Services Research-Malignant Diseases: Quality Of Life Studies Source Type: research

Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry
ConclusionsFor acromegaly patients being treated at specialized centres, the incidence of MIs and strokes does not seem to differ from the general population. Certainty regarding such statements requires large, prospective studies however.
Source: Pituitary - August 14, 2017 Category: Endocrinology Source Type: research

Recurrent stroke in childhood cancer survivors
Conclusion: Survivors of childhood cancer, particularly those previously treated with high-dose cranial radiation, have a high risk of recurrent stroke for decades after a first stroke. Although these strokes are mostly occurring in young adulthood, hypertension, an established atherosclerotic risk factor, independently predicts recurrent stroke in this population.
Source: Neurology - September 21, 2015 Category: Neurology Authors: Fullerton, H. J., Stratton, K., Mueller, S., Leisenring, W. W., Armstrong, G. T., Weathers, R. E., Stovall, M., Sklar, C. A., Goldsby, R. E., Robison, L. L., Krull, K. R. Tags: Childhood stroke, Stroke in young adults, All Cerebrovascular disease/Stroke, Primary brain tumor ARTICLE Source Type: research

E-006 Familial Incidence of the Congenital Torcular Dural Arteriovenous Shunt
Purpose There are several hereditary disorders that are well known to be associated with arteriovenous malformations (AVMs) involving the central nervous system including Sturge-Weber, Klippel-Trenaunay-Weber, and Parkes-Weber syndromes as well as hereditary haemorrhagic telangiectasia and hereditary neurocutaneous angiomatosis. Furthermore, familial incidence of AVMs in the absence of congenital hereditary disorders also has been reported. Herein, we describe the occurrence of the giant torcular herophili (TH) dural arteriovenous fistula (AVF) in two pediatric cousins treated with endovascular embolization. Case report C...
Source: Journal of NeuroInterventional Surgery - July 26, 2014 Category: Neurosurgery Authors: Honarmand, A., Hurley, M., Daruwalla, V., Ansari, S., Shaibani, A. Tags: Electronic poster abstracts Source Type: research

Radiation, Atherosclerotic Risk Factors, and Stroke Risk in Survivors of Pediatric Cancer: A Report From the Childhood Cancer Survivor Study
Conclusion: Young adult pediatric cancer survivors have an increased stroke risk that is associated with CRT in a dose-dependent manner. Atherosclerotic risk factors enhanced this risk and should be treated aggressively.
Source: International Journal of Radiation Oncology * Biology * Physics - May 15, 2013 Category: Radiology Authors: Sabine Mueller, Heather J. Fullerton, Kayla Stratton, Wendy Leisenring, Rita E. Weathers, Marilyn Stovall, Gregory T. Armstrong, Robert E. Goldsby, Roger J. Packer, Charles A. Sklar, Daniel C. Bowers, Leslie L. Robison, Kevin R. Krull Tags: Pediatric Cancers Source Type: research